About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

TNRCoverWeb120.jpg Buy on Amazon

Brain Waves

Monthly Archives

September 20, 2007

September 18, 2007

NASDAQ and NeuroInsights Launching Neurotech Index Sept. 25

Email This Entry

Posted by Zack Lynch

Huge news. Next Tuesday, the NASDAQ NeuroInsights Neurotech Index will go live (ticker symbol: NERV). It has been nearly five years since we came up with the concept for a public neurotech index to track the performance of the industry and now this vision is about to become a reality.
Toni Clarke of Reuters breaks the news in her exclusive story Nasdaq picks brain for new health care index

BOSTON (Reuters) - Research and investment into brain-related illnesses is growing at an unprecedented rate as scientific advances coincide with the demands of an aging baby-boom population determined to beat the odds.

Now, investors looking to place bets on this fast-growing but highly specialized sector can.

Nasdaq Stock Market Inc is poised to launch an index made up of companies whose primary focus is the development of drugs, devices and diagnostics to treat neurological disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia.

It is one of the first indexes ever to focus on a specific disease category, and Nasdaq expects it to interest several types of investors, from individuals touched by a particular disorder to those seeking to minimize the risk of stock-picking in a complicated industry.

"This index will be the defining metric for performance of companies in this very important segment of the health field," said Steven Bloom, senior vice president, Nasdaq Financial Products.

The index, to be called the Nasdaq NeuroInsights Neurotech Index, will launch on September 25 and has been created in conjunction with NeuroInsights, a research firm that monitors and analyzes trends in the neurotechnology field.

Companies in the 32-member index include drug makers such as Biogen Idec, which makes the multiple sclerosis drugs Avonex and Tysabri; device makers such as Northstar Neuroscience, which makes brain stimulation devices to help treat stroke and depression; and diagnostic companies such as Natus Medical. Together, they have a combined market value of more than $71 billion.

...To qualify for inclusion in the index, a company must be a "pure play" neurology company, deriving some 50 percent or more of its revenue from treatments for central nervous system disorders, or devoting 50 percent or more of its research and development dollars to the field.

According to a report by NeuroInsights, global sales of pharmaceuticals for neurological disorders grew 8.5 percent to $101 billion in 2006, compared to a 7 percent growth rate for the overall pharmaceuticals market.

And Zack Lynch, co-author of the report, said venture capitalists are plowing money into the field, with investment rising 7.5 percent in 2006 to $1.67 billion.

"The aging of the baby-boom generation is creating a substantial market opportunity," he said.

More neurotech index news to follow as we launch the index with a host a brain industry CEO media tour in NYC next week. Click to read full Reuters article.

Comments (0) + TrackBacks (0) | Category: Neurotech Industry

September 10, 2007

Briefing the U.S. Intelligence Community on Neurotech

Email This Entry

Posted by Zack Lynch


Last month I was invited by the Defense Intelligence Agency to brief a special committee on the current and future state of neurotech in Washington DC at the National Academy of Sciences. The Committee on Military and Intelligence Methodology for Emergent Neurophysiological and Cognitive/Neural Science Research in the Next Two Decades is working on a study to identify the trends in brain research that may help the U.S. Intelligence Community anticipate the state of such research internationally in the year 2027.

I was one of about a dozen speakers brought in for this intense two day session. I started off by providing an extensive overview of NeuroInsights latest neurotech market and investment information. I then honed in on the transformative impact the passage of the National Neurotechnology Initiative (NNTI), a program I have been spearheading within NIO, the trade association I launched last year, could have on the global brain industry landscape. The NNTI is a newly proposed $200M/year Federal research and development program designed to coordinate strategic investment across multiple government agencies to accelerate the development of vitally important areas of the field.

In addition to making the case that the development of new drugs and devices for the brain and nervous system are critical to U.S. national defense and warfighter rehabilitation, I argued that huge quality of life improvements and economic payoffs will accrue to the countries that successfully nurture the emerging neurotechnology industry. Moreover, the NNTI will not only stimulate economic growth in the United States, but like other visionary Federal R&D initiatives like the Human Genome Project will spur greater public investment among all nations seeking a competitive voice in the fast growing global industry known as neurotech.

Comments (1) + TrackBacks (0) | Category: NIO

September 6, 2007

Rules for Renegades

Email This Entry

Posted by Zack Lynch

Renegade entrepreneur, Christine Comaford-Lynch has published an epic book on how to make your life dreams come true. Rules for Renegades: How to Make More Money, Rock Your Career and Revel in Your Individuality is already rocketing up the best-seller charts, and is a must read for anyone wanting more from life. As my sister-in-law, I can testify to the fact that she lives a magnificent life. From model to monk to multi-millionaire, she has always gone after what she wants—and gotten things done. She’s won, lost, worked, played, and every step of the way, she’s written her own rules. Now Christine is ready to tell her story. Buy the book today for you and a friend and visit her website for lots of free, very cool, resources. It guaranteed to motivate the renegade in you!

Comments (0) + TrackBacks (0) | Category: X-tra

September 5, 2007

September 4, 2007

Neurotech Reports 7th Neurotech Leaders Forum, Oct 25-26

Email This Entry

Posted by Zack Lynch

Now in its seventh year, Jim Cavuoto is hosting the annual Neurotech Leaders Forum Conference on October 25-26 at the Radisson Hotel, Newport Beach, CA. This two-day conference offers an exclusive forum for neurodevice executives and entrepreneurs to interact with investors, technologists, and potential partners who are actively working to grow this new and exciting industry. Among the many interesting sessions are the Consumer/End User Panel, the panel on the Psychiatric Disorders Frontier and more prosaically the Reimbursement panel on which I will be speaking. Please come share your input on how NIO can help your company and our industry grow. See you there.

Comments (0) + TrackBacks (0) | Category: Neurodevices